Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies.

Autor: Charalampous C; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Goel U; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Kapoor P; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Binder M; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Buadi F; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Dingli D; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Dispenzieri A; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Fonder A; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Gertz M; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Gonsalves W; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Hayman S; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Hobbs M; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Hwa YL; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Kourelis T; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Lacy M; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Leung N; Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN., Lin Y; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Warsame R; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Kyle RA; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Rajkumar V; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN., Kumar SK; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: kumar.shaji@mayo.edu.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct; Vol. 24 (10), pp. e329-e335. Date of Electronic Publication: 2024 Jun 01.

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Autor: Vaxman I; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi F; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hwa Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hobbs M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman S; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Grogan M; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA., Go R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Siddiqui M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA. dispenzieri.angela@mayo.edu.

Publikováno v: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1866.

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.

Autor: Zanwar S; Division of Hematology, Mayo Clinic, Rochester, MN, US., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, US., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, US., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, US., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, US., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, US., Go RS; Division of Hematology, Mayo Clinic, Rochester, MN, US., Hayman S; Division of Hematology, Mayo Clinic, Rochester, MN, US., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, US., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, US., Cook J; Division of Hematology, Mayo Clinic, Rochester, MN, US., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, US., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, US., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, US., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, US., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN, US., Hobbs M; Division of Hematology, Mayo Clinic, Rochester, MN, US., Hwa YL; Division of Hematology, Mayo Clinic, Rochester, MN, US., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, US., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, US., Kumar S; Division of Hematology, Mayo Clinic, Rochester, MN, US., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, US. dispenzieri.angela@mayo.edu.

Publikováno v: Leukemia [Leukemia] 2024 Jun; Vol. 38 (6), pp. 1423-1426. Date of Electronic Publication: 2024 Apr 09.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

'Real-life' data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Autor: Vaxman, I., Abeykoon, J., Dispenzieri, A., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Reeder, C., Sher, T., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Go, R., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Kristen, McCullough, Kapoor, P., Gertz, M. A.

Publikováno v: Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Blood Cancer Journal

Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc50bffc70fcd57cf980408a92adcf6
https://doaj.org/article/052538cf28fe46f1b641764536e6bd67